Evaxion A (EVAX) EBIT Margin (2024 - 2025)
Evaxion A (EVAX) posted EBIT Margin of 39.94% for Q3 2025, up 100.34% quarter-over-quarter from 11729.73% in Q2 2025, and up 9731.0% year-on-year from 0.41% in Q3 2024.
Evaxion A (EVAX) EBIT Margin (2024 - 2025) Analysis & Trends
Evaxion A (EVAX) has reported EBIT Margin for 2 consecutive years, with 39.94% the latest figure, recorded in Q3 2025.
- EBIT Margin for Q3 2025 came in at 39.94%, up 9731.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 191.88% (up 23945.0% YoY), and the FY2025 annual result was 122.66%, up 31789.0% from the prior year.
- EBIT Margin was 39.94% for Q3 2025 at Evaxion A, up from 11729.73% in the prior quarter.
- Over five years, EBIT Margin peaked at 39.94% in Q3 2025 and troughed at 11729.73% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 20.09% |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 16.51% |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 38.10% |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -6.78% |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 17.83% |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 30.35% |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 23.02% |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | - |
| 10 | Evaxion A | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.34% |
| Jun 30, 2025 | -11,729.73% |
| Dec 31, 2024 | -3,298.36% |
| Sep 30, 2024 | -57.37% |
| Jun 30, 2024 | -2,974.68% |
| Mar 31, 2024 | -8,619.61% |